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using hemodiafiltration rather than standard hemodialysis
and dialysing patients for a modal dialysis session time
of 4.5 h, only a minority of patients were able to achieve
the KDOQI and previous UK Renal Association blood
pressure targets,3 in keeping with our multicenter study.4
The UK Renal Association, recently revised its guidelines
and withdrew specific targets for pre- and post-dialysis
blood pressure, on the basis of a lack of evidence-based
data.5
However this does not necessarily imply that blood
pressure control is not important for hemodialysis
patients. It may be that, compared to the general
population, the etiology of hypertension may be more
complex, although sodium and volume overload play an
important role in determining blood pressure control.6 In
addition, although pre- and post-hemodialysis blood
pressure recordings are relatively simple to perform in
clinical practice, they may not accurately reflect inter-
dialytic blood pressure control.
Intradialytic hypotension remains a major side effect of
standard outpatient hemodialysis,7 and is, in part, related to
interdialytic weight gain and increased ultrafiltration
requirement.8 One potential side effect of strict pre- and
post-blood pressure targets could be an increased incidence
of symptomatic intradialytic hypotension. Intradialytic
hypotension has been shown to be associated with both
myocardial and cerebral ischemia,9 and in particular
repetitive myocardial stunning could exacerbate myocardial
fibrosis and so potentially predispose to cardiac arrhyth-
mias. Thus, although blood pressure control is a vital part in
the management of the hemodialysis patient, more study is
required to determine which blood pressure measurements
should be used for setting any future clinical target.
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To the Editor: To the best of our knowledge, human studies
and meta-analyses on low-protein diets as a measure for the
prevention of progression of renal disease have never
differentiated between sources of protein.1,2 We therefore
read with great interest the report by Phisitkul et al.,3 in
which it is shown that a diet in which protein is derived from
casein is associated with a more rapid decline in glomerular
filtration rate in remnant kidneys in rats than a diet in which
protein is derived from soy. Large variation in effect of low-
protein diets on progression of renal disease between
different human studies may therefore be the consequence
of variation in the prescription of the preferred source of
protein in a low-protein diet rather than the consequence of
publication bias favoring low-protein diets.1 In our opinion,
the study by Phisitkul et al. challenges the currently held view
that the benefit of a low-protein diet in slowing down
progression in human renal disease is negligible.4 New studies
and meta-analyses should be performed in which sources of
protein and potentially individual amino acids are taken into
account before it is decided whether the effect is negligible for
all low-protein diets.
Phisitkul et al. performed additional experiments and
analyses from which they conclude that the casein-induced
renal injury is mediated by metabolic acidosis through
endothelin A receptors. Their conclusion that metabolic
acidosis is important is substantiated by experiments in
which they show that rats on casein diet have metabolic
acidosis and that decline in glomerular filtration rate can be
prevented by alkalinization with either sodium bicarbonate
(if concomitant blood pressure elevation by the associated
increase in sodium intake was treated) or CaHCO3. The
authors also performed experiments in which they show that
treatment with darusentan can prevent the decline in
glomerular filtration rate occurring in rats on casein diet.
As far as we can oversee, however, the authors did not
perform experiments reported in the paper that substantiate
their overall conclusion that casein-induced renal injury is
mediated by metabolic acidosis through endothelin A
receptors. In the experiments they performed, neither daily
net acid excretion, NH4
þ excretion, nor total acid excretion in
urine was affected by darusentan treatment. Systemic
metabolic acidosis in rats on casein diet was also not affected
by treatment with darusentan. Thus, treatment with
darusentan seems to block the deleterious effect of casein
diet on renal injury independent of its effect on metabolic
acidosis rather than dependent on it. It is important that this
issue is clarified, because acknowledgment of independent
pathways holds the prospect of identification of intriguing
Kidney International (2008) 74, 1623–1627 1625
l e t t e r t o t h e e d i t o r
new pathophysiological mechanisms, and performance of
clinical trials in which additive or even synergistic beneficial
effects of treatment with dietary alkalinization and darusen-
tan on progression of renal disease could be demonstrated.
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We thank Dr Bakker, Dr Gans, and Dr Navis for their
interest in our recent KI publication1 linking diet-induced
metabolic acidosis, endothelin receptors, and progressive
nephropathy in the remnant kidney model of chronic
kidney disease (CKD). We agree that our studies support
the need for human studies to examine the effect of source
of dietary protein, rather than the amount of dietary
protein2,3 on progression of CKD. Our earlier studies4
showed that dietary protein as casein that increases
intrinsic acid production induces greater tubulointerstitial
injury in Munich–Wistar rats with intact nephron mass
than dietary protein as soy that does not increase intrinsic
acid production.4 Despite greater tubulointerstitial injury
induced by dietary casein, whole-kidney glomerular
filtration rate (GFR) was not different from the animals
eating dietary soy after 96 weeks.4 Our more recent
publication on which the said investigators comment
shows that dietary casein induced greater GFR decline
than dietary soy after 12 weeks.1 Our earlier study links
tubulointerstitial injury to the increased intrinsic acid
production induced by dietary casein1 and our more
recent study links GFR decline to metabolic acidosis
induced by dietary casein.4 Use of selective endothelin
receptor antagonists support that the tubulointerstitial
injury in the intact kidney1 and GFR decline in the
remnant kidney4 are mediated through endothelin recep-
tors. Together, these data support that dietary casein-
induced increased intrinsic acid production is injurious to
the kidney but that this injury is more likely to lead to GFR
reduction in the remnant than the intact kidney of
Munich–Wistar rats. The investigators apparently agree
with these points.
The investigators question if the data reported1
substantiate our conclusion that casein-induced kidney
injury is mediated by metabolic acidosis and through
endothelin receptors. They state correctly that neither
daily excretion of net acid, NH4
þ , nor total acid was
affected by darusentan, the endothelin A antagonist that
ameliorated tubulointerstitial injury in animals with intact
nephron mass4 and ameliorated GFR decline in remnant
kidneys.1 The investigators also correctly state that
darusentan did not affect the casein-induced systemic
metabolic acidosis in these animals with remnant kidneys.
They agree that the data reported support that darusentan
ameliorates the deleterious effects of dietary casein on GFR
of remnant kidneys but they argue that the data described
above support that these beneficial effects of darusentan
are independent of its effects on metabolic acidosis.
The last sentence of the abstract of our publication1 says
‘Our study suggests that the casein-induced decline in GFR
of the remnant kidney is mediated by metabolic acidosis
through endothelin A receptors’ (italics added). Our point is
that metabolic acidosis induced by dietary casein induces
the injury that leads to GFR decline through endothelin
receptors. We do not state or mean to imply that darusentan
exerts its beneficial effects to ameliorate GFR decline by
reducing metabolic acidosis that then leads to an ameliora-
tion of GFR decline in remnant kidneys as apparently
suggested by the investigators. Instead, we think that our
data support the following scenario: dietary acid increases
intrinsic acid production and metabolic acidosis, leading to
stimulated kidney endothelin production as supported by
increased urine endothelin excretion (Table 4), and the
increased kidney endothelins then cause kidney injury that
reduces GFR through endothelin A receptors.1 We agree
with the investigators that darusentan renders its beneficial
effects independent of metabolic acidosis. The point of our
manuscript, however, is that the described beneficial effects
of endothelin A receptor antagonism provided by darusen-
tan is not by ameliorating metabolic acidosis but instead is
by inhibiting the effects of increased kidney endothelin
activity induced by metabolic acidosis that was in turn
induced by dietary casein. In fact, our earlier studies4,5 show
that increased kidney tubule acidification in remnant
kidneys is mediated through endothelin B, and specifically
not endothelin A, receptors. Consequently, we did not
expect the endothelin A receptor antagonist to affect kidney
acidification and this was indeed the case.1
As stated, we support the call issued by these
investigators to test the hypothesis that the source of
dietary protein can influence the rate of GFR decline in
CKD. Specifically, we hypothesize that diets high in
acid-producing amino acids are associated with faster
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